GRADE & PURITYMoligand™?Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools.
Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Calculateurs de solution
Molarity Calculator
Determine the necessary mass, volume, or concentration for preparing a solution.
Dilution Calculator
Determine the dilution needed to prepare a stock solution.
Reconstitution Calculator
Avis
Avis des clients
Application Protocols
No validated application protocols are provided for EVP-21 in this listing. The following is general, non-binding guidance for handling small molecules in screening workflows.
Example workflow (general)
Verify identity/purity from CoA; optionally confirm by LC–MS/HPLC.
Perform a mini solubility/stability check in DMSO (and intended assay buffer). If soluble and stable, prepare a master stock at an appropriate concentration (e.g., 10–50 mM) in DMSO; filter (0.2 µm PTFE) if needed.
Create a dilution series in DMSO and back-dilute into assay buffer, keeping final DMSO ≤0.5–1% v/v unless the assay tolerates higher.
Include vehicle controls and, where relevant, counterscreens for assay interference (fluorescence quenching, redox cycling, detergent sensitivity).
Store working plates at controlled temperature, protected from light and evaporation; minimize freeze–thaw cycles.
Analytics (general)
Track carryover/adsorption by including pre- and post-run blanks in LC–MS/HPLC methods. Use low-bind plastics when necessary.
Documentation
Record lot number, concentration, solvent composition, preparation date, and storage conditions on plate maps and in your ELN.
Item-specific note
Any protocol parameters unique to EVP-21 (e.g., solubility ceilings, light sensitivity) are not specified here and should be derived from the CoA/SDS or preliminary bench tests.
Biological Roles
Item-specific biological information
No biological function, target class, or pathway association is provided for EVP-21 in this listing. Do not infer pharmacology or therapeutic relevance. Research use only.
General considerations for screening compounds (general knowledge)
Compounds in discovery libraries may display assay-dependent activities. Any apparent effect should be validated through orthogonal assays (biochemical vs. biophysical), counterscreens (e.g., reporter interference, redox cycling), and control experiments (detergent, metal chelators where appropriate).
Confirm colloidal aggregation status (e.g., dynamic light scattering, detergent sensitivity) for hits from high-throughput screens to exclude nuisance mechanisms.
Establish basic ADME-relevant properties experimentally if needed for follow-up studies: permeability surrogates (PAMPA), microsomal stability, and protein binding can be informative, but are outside the scope of this listing.
Data integrity and provenance
Record the exact lot, solvent vehicle, and plate map for each assay. Carry forward the CoA and SDS with your data package.
Caution
EVP-21 is not supplied with claims of biological activity or selectivity. Any biological role must be determined empirically by the end user.
Buffer Applications
EVP-21 is a research small molecule and is not a buffering agent.
Applicability
Not typically used to prepare buffer systems. No pKa or acid/base functionality is specified that would recommend it as a titratable buffer component.
Practical note
For aqueous assays involving EVP-21, prepare the buffer system independently using established buffers (e.g., PBS, HEPES, MES, Tris) and then introduce EVP-21 from a compatible stock solution (often DMSO or ACN), ensuring the final co-solvent level is acceptable for the assay. Verify compound solubility to prevent precipitation.
Item-specific data
pKa, aqueous solubility, and ionic state vs. pH: Not specified for this item; refer to CoA/Spec Sheet.
Green Alternatives
Because EVP-21’s structure and use-mode are not specified, green chemistry considerations focus on solvent and process choices around handling, analysis, and any optional derivatization.
Greener solvent choices (general guidance)
Prefer ethanol, isopropanol, ethyl acetate, 2-methyltetrahydrofuran (2-MeTHF), and water/buffered systems when performance allows.
2-MeTHF vs THF: similar utility in extractions/medium-polar reactions; 2-MeTHF offers better safety/greenness and lower peroxide risk than THF (literature), but verify compound solubility.
Ethyl acetate vs DCM: often an effective, lower-impact replacement for extractions and normal-phase chromatography.
ACN vs MeOH: ACN offers lower viscosity and strong elution power for LC; MeOH is generally safer and cheaper—use whichever delivers acceptable resolution.
Operational greening
Scale reactions and assays at the minimum effective volume. Use microplate formats to reduce solvent use.
Implement solvent recycling (ACN/MeOH) in analytical labs and collect segregated waste streams to maximize recovery.
Favor room-temperature chemistry/assays where compatible (as stability allows) to cut energy use.
Item-specific note
No hazard or persistence data are provided for EVP-21. Apply your institution’s green chemistry framework and consult the SDS when choosing media and disposal routes.
Pharmaceutical Uses
Regulatory/compendial status
No pharmacopeial monograph or excipient designation is provided or implied for EVP-21. It is supplied strictly for research use only.
Formulation context (general information for research settings)
In discovery biology, small molecules are commonly handled as DMSO stocks and diluted into assay media. For in vitro-only workflows, consider solubilization aids (co-solvents, cyclodextrins, pH adjustment) if solubility is limiting. These are research practices, not pharmaceutical product recommendations.
Manufacturing/clinical use
None claimed. Do not use in humans or for diagnostic/therapeutic applications.
Documentation
If your QA/QC processes require, retain the CoA, SDS, and any vendor spectral data. For GLP-adjacent studies, verify identity/purity analytically before use.
Item-specific note
Any claims regarding dosage forms, routes of administration, or therapeutic classes are out of scope and not provided for this item.
Physical Properties
Item-specific physicochemical data are not listed in the current entry. Do not assume values; confirm against the CoA/Spec Sheet before method development.
Item-specific values
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
Melting point: Not specified for this item; refer to CoA/Spec Sheet.
Boiling point: Not specified for this item; refer to CoA/Spec Sheet.
Density: Not specified for this item; refer to CoA/Spec Sheet.
Solubility: Not specified for this item; refer to CoA/Spec Sheet.
LogP/logD: Not specified for this item; refer to CoA/Spec Sheet.
pKa: Not specified for this item; refer to CoA/Spec Sheet.
Refractive index: Not specified for this item; refer to CoA/Spec Sheet.
General guidance for unknown small molecules (literature/practice)
Do a rapid solubility screen in DMSO, DMF, methanol, ethanol, acetonitrile, ethyl acetate, toluene, and water/phosphate buffer (pH 7.4) to inform assay preparation.
For solid compounds, assess hygroscopicity by mass drift under ambient vs. desiccated conditions.
If UV detection is planned (HPLC/UPLC), record a 200–400 nm scan in several solvents to identify λmax and any strong background absorbance.
Where stability is uncertain, perform small-scale stress tests (50 °C, light exposure, pH 2/7/10) and monitor by LC–MS for degradation pathways.
Note
Treat all numbers from third-party sources as literature values until confirmed on the delivered lot via CoA/SDS.
Quality and Grades
Item-specific grade
Grade/Purity: Moligand™ (as provided). This designation indicates placement within Aladdin’s discovery-oriented small-molecule/ligand library. Specific assay suitability criteria (e.g., HPLC purity threshold, residual solvent limits) are not listed here and should be confirmed on the CoA/Spec Sheet for the supplied lot.
What Moligand™ typically implies (general description)
Intended use in screening, hit triage, and chemical biology research—research use only.
Identity typically supported by orthogonal methods (e.g., LC–MS and 1H NMR) and purity fit-for-purpose for screening; exact specifications vary by item and lot and must be verified on the CoA.
Packaging sized to facilitate plate-based workflows and parallel experiments.
Considerations for analytical users (general)
If sub-ppm metal content, residual water limits, or specific UV cutoff are critical (e.g., for photochemical assays or trace analysis), obtain the lot-specific CoA or request an enhanced QC package. Item-specific limits are not provided in this listing.
If you plan to file data to regulatory repositories, retain the CoA, SDS, and any vendor spectral data in your ELN.
Stabilizers/additives
None are declared in this entry. If stabilizers or salt forms are present, they will appear on the CoA/Spec Sheet.
Reaction and Applications
Item-specific application claims
No manufacturer application notes are provided for EVP-21 in this listing. Do not infer therapeutic or target claims. Research use only.
Likely research contexts for a Moligand™ library member (general)
Small-molecule screening in biochemical or cell-free assays to identify preliminary activity signals.
Tool-compound exploration in chemical biology for mechanism hypothesis generation, followed by orthogonal validation.
Analytical reference: retention-time markers, LC–MS method development, or spike-and-recovery exercises.
If employing in reactions (general considerations)
EVP-21 is not positioned as a synthetic reagent here. If you choose to derivatize or incorporate it into SAR analogs, first establish functional group tolerance and stability under the planned conditions (acid/base, nucleophiles, oxidants, heat, and light).
Conduct micro-scale scouting reactions and monitor by LC–MS to identify degradation or rearrangement pathways.
Assay development tips (general)
Establish a solubility/stability envelope in your intended assay matrix. Include counterscreens for aggregation (e.g., detergent controls) and redox interference where applicable.
Use dose–response curves with adequate top concentration below the kinetic solubility limit to avoid false positives from precipitation.
Documentation
Capture lot number, preparation route, solvent composition, and storage history for data integrity and reproducibility.
Reaction Conditions
No reaction conditions can be specified for EVP-21 as a reagent because the functional groups and reactivity are not provided in this listing.
If using EVP-21 in derivatization (general guidance)
Solvent: Choose based on solubility (DMSO, DMF, MeCN, 2-MeTHF, toluene, EtOAc). Validate compatibility with the functional groups present.
Temperature: Start at ambient and increase cautiously after confirming stability by TLC/LC–MS.
Atmosphere: Use inert atmosphere (N2/Ar) for air/moisture-sensitive transformations once sensitivity is known.
Catalysts/bases/acids: Select according to the identified functional groups (e.g., Pd for cross-coupling if aryl halides present; carbodiimide/uronium reagents for amide couplings). Avoid strong conditions until stability is established.
Workup/purification: Prefer benign solvents and normal-phase flash or reverse-phase prep HPLC as appropriate.
Expected yields and kinetics
Not applicable for this item; consult literature after structure confirmation.
Control experiments
Always run stability blanks of EVP-21 in the chosen solvent/base/acid at reaction temperature to benchmark inherent degradation.
Safety and Handling
Safety data for EVP-21 are not fully specified in this listing. Always consult the product SDS and your institutional safety protocols before use.
Item-specific hazard information
GHS classification: Not specified for this item; refer to SDS.
Signal word: Not specified for this item; refer to SDS.
H-statements/Pictograms: Not specified for this item; refer to SDS.
General prudent practices for small molecules (general guidance)
PPE: Laboratory coat, safety glasses, and suitable chemical-resistant gloves (e.g., nitrile). Work in a fume hood to avoid inhalation of dusts or vapors.
Avoid skin/eye contact and inhalation; prevent ingestion. Wash hands thoroughly after handling.
Incompatibilities: Unknown for this item. Until confirmed, avoid strong oxidizers/reductants, strong acids/bases, and reactive metals. Keep away from ignition sources if the solvent system is flammable.
First aid (overview; defer to SDS for specifics):
Skin/eye contact: Rinse with water for several minutes; remove contaminated clothing; seek medical attention if irritation persists.
Inhalation: Move to fresh air; obtain medical advice if symptoms occur.
Ingestion: Rinse mouth; do not induce vomiting; seek medical attention.
Waste and spill response (general)
Contain small spills with inert absorbent; collect for disposal as organic chemical waste. Decontaminate surfaces with appropriate solvent/detergent.
Dispose of according to local regulations and your EHS guidance.
Stability/Decomposition
Not specified for this item; verify thermal/light stability on receipt. Protect from moisture and light until stability is confirmed.
Solvent Selection
Without a declared structure for EVP-21, select solvents empirically based on rapid solubility and stability screens.
Polar aprotic: DMSO, DMF, NMP, acetonitrile (often preferred for primary DMSO stock solutions and LC–MS sample prep).
Protic: Methanol, ethanol, isopropanol (useful for UV work and preparative steps; watch for transesterification or solvolysis if the molecule is labile).
Aqueous systems: Water and phosphate buffers (pH 2–9) with or without co-solvent (≤1–2% DMSO or ACN) for biochemical assays.
Less polar/organic: Ethyl acetate, THF/2-MeTHF, toluene, dichloromethane for extractions or nonaqueous manipulations.
Miscibility and handling tips (general)
Prepare concentrated DMSO stocks (e.g., 10–50 mM) only after confirming solubility and stability; avoid freeze–thaw cycling of DMSO plates.
When diluting DMSO stocks into buffers, add compound slowly with vortexing/sonication to avoid precipitation; keep final DMSO ≤0.5–1% for sensitive biochemical assays.
For LC–MS, select injection solvents close to mobile phase composition to reduce peak distortion and precipitation.
Selection relative to alternatives (general)
If poor aqueous solubility is observed, consider cyclodextrin inclusion, mild cosolvent blends (ACN, MeOH), or pH adjustment around ionizable groups once pKa is known.
Item-specific note
Definitive solvent recommendations depend on EVP-21’s structure and ionization behavior, which are not specified here. Verify empirically and consult the CoA/Spec Sheet.
Storage and Reconstitution
Item-specific storage
Storage conditions: Room temperature (as provided).
Shipped in: Not specified for this item; refer to CoA/Spec Sheet.
Appearance: Not specified for this item; refer to CoA/Spec Sheet.
General storage best practices for small molecules
Keep container tightly closed, in a dry place, protected from direct light. Use desiccant if hygroscopic behavior is suspected. Record first-open date.
For long-term retention of analytical integrity, many users store solid materials at ambient or 2–8 °C depending on stability; confirm with the SDS/CoA before deviating from the vendor recommendation.
Solvent choice: Start with anhydrous DMSO for master stocks if compatible; alternatives include MeOH, EtOH, or MeCN. Confirm solubility and chemical stability prior to scaling.
Procedure:
Allow vial to equilibrate to room temperature in a desiccator.
Briefly spin down contents to collect material at the bottom cap.
Add a measured volume of solvent to reach the desired concentration (e.g., 10–50 mM), vortex, and sonicate gently if needed.
If particulates remain, warm slightly (≤40 °C) or reduce concentration.
Optionally sterile-filter through 0.2 µm PTFE if required by the application.
Aliquoting: Dispense into single-use aliquots to avoid repeated freeze–thaw or evaporation cycles.
Stability after reconstitution
Not specified for this item; verify by re-injection on LC–MS/HPLC over time under intended storage (e.g., RT, 4 °C, or −20 °C) to establish hold times.
Research use note
For research use only.
Structure and Identity
Brief overview: EVP-21 (SKU E610232) is offered as a research-only small-molecule entry in our Moligand™ collection. Item-specific structural information is limited in the current listing.
Item-specific facts (from Product Data)
Product name: EVP-21
CAS: 2742654-01-7
PubChem CID: 165715979
InChIKey: 109310 (as provided; note that typical InChIKeys are 27 characters. Refer to CoA/Spec Sheet for confirmation.)
SMILES: Not specified for this item; refer to CoA/Spec Sheet.
Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
Interpreted structural features
Structural motifs, functional groups, ring systems, and stereochemistry cannot be detailed without an authoritative structure. Please consult the CoA/SDS or contact Aladdin Scientific for the definitive structural representation.
2D structure (descriptive)
Not available in this listing. Once the structure is confirmed, a 2D description (e.g., aromatic scaffolds, heteroatom pattern, stereocenters) can be provided for cheminformatics workflows.
Identifier cross-check guidance (general)
For screening collections, verify identity by matching CAS/CID/InChIKey/SMILES across your ELN/LIMS. If discrepancies appear (e.g., abbreviated InChIKey), prioritize the CoA/Spec Sheet and vendor SDS as the source of truth.
Synthetic Utility
Item-specific assessment
EVP-21 is offered as a screening compound; no functional group information is provided, so specific synthetic transformations cannot be recommended. Treat it primarily as a final compound rather than a reagent or building block unless you have structural confirmation.
General strategies if derivatization is desired (general guidance)
Confirm the molecular structure (CoA, NMR, LC–MS) and identify modifiable positions (e.g., halogens, anilides, esters, heteroaryl substituents) before planning SAR derivatization.
Begin with mild conditions (e.g., amide couplings, SNAr on activated heteroarenes, Suzuki-Miyaura if aryl halides/boronates are present). Escalate to stronger conditions only after stability screening.
Protect potentially labile groups during multistep sequences, and track mass balance with LC–MS to identify side products.
Analytical support
Establish a robust HPLC/UPLC method and at least one orthogonal purity metric (e.g., quantitative 1H NMR) to track modifications and confirm material quality.
Retrosynthetic considerations
Without a known scaffold, generic disconnections (amide formation, C–N/C–C cross-coupling, esterification) may be considered only after structural elucidation. Avoid speculative chemistry until the exact structure is validated.
Target Specificity
No target, binding partner, or selectivity profile is provided for EVP-21 in this listing.
Item-specific data
Target/epitope/biomolecule: Not specified for this item; refer to CoA/Spec Sheet or your internal screening data.
General guidance
Any claims of specificity must be established empirically using orthogonal assays (e.g., biochemical inhibition/activation, biophysical binding such as DSF/SPR/ITC, and appropriate counterscreens). Report potency with full concentration–response curves and replicate statistics.
Note
EVP-21 is part of a research compound library (Moligand™). No biological specificity is implied by this designation.
Need help choosing the grade?
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
